163
Participants
Start Date
September 30, 2011
Primary Completion Date
May 31, 2013
Study Completion Date
November 30, 2013
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Administered by im injection, twice during the study, three months apart
Manhattan Medical Research, New York
Staten Island Urological Research, PC, Staten Island
Brooklyn Urology Research Group, Brooklyn
The Urological Institute of Northeastern New York, Albany
The Premier Medical Group of the Hudson Valley, PC, Poughkeepsie
Urologic Consultants of SE PA, Bala-Cynwyd
Urology Health Specialists, LLC, Bryn Mawr
Mid Atlantic Clinical Research, Greenbelt
Urology of Virginia, Virginia Beach
PMG Research of Winston Salem, Winston-Salem
PMG Research of Wilmington, Wilmington
Carolina Urologic Research Center, Myrtle Beach
Greenville Health System, Greer
Atlantic Urological Associates, Daytona Beach
Winter Park Urology Associates, PA, Orlando
Coastal Medical Center, Sarasota
Urology Health Team, Ocala
Urology Associates, PC, Nashville
First Urology, Jeffersonville
Urology San Antonio Research, PA, San Antonio
Idaho Urologic Institute, Meridian
North Idaho Urology, Coeur d'Alene
Genesis Research, San Diego
Seattle Urology Research Center, Burien
Premier Urology Associates, LLC, Lawrenceville
Lead Sponsor
GP-Pharm
INDUSTRY